Skip to content
Strength & muscleObservational meta-analysis3 min read

Diabetes is linked to about twice the odds of sarcopenia across 16 observational studies

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies. · Frontiers in endocrinology · 2021 · Original paper ↗

Key takeaway

In a meta-analysis of 16 observational studies, people with diabetes had higher odds of sarcopenia than people without it (combined OR 2.09, 95% CI 1.62 to 2.70, from 7 studies). Because the studies are observational and the abstract repeats the same OR for the complications analysis, the exact size and its causal meaning are uncertain.

Study design

Observational meta-analysis

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

Diabetes and age-related muscle loss often appear together, but the evidence has been scattered across blood sugar levels, prediabetes, diabetes and its complications. The authors pooled observational studies to see how HbA1c, prediabetes, diabetes and diabetic complications relate to sarcopenia.

Who and how

Meta-analysis of observational studies. PubMed, Embase, Cochrane and Web of Science were searched from inception to May 2021 for full-text English articles reporting the prevalence of sarcopenia in patients with and without diabetes. Study quality was assessed with the Newcastle-Ottawa scale. The abstract does not report the statistical model, heterogeneity or participant numbers.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    16 studies were included in the meta-analysis.
  2. 2
    Seven studies found people with diabetes had a higher risk of sarcopenia than those without diabetes (combined OR 2.09, 95% CI 1.62 to 2.70).
  3. 3
    Three studies showed high HbA1c levels were associated with loss of muscle mass, and one study found people with prediabetes had lower muscle mass, strength and performance than people without diabetes.
  4. 4
    The other five studies suggested diabetic complications increased the risk of sarcopenia, but the abstract gives the same combined estimate for them (OR 2.09, 95% CI 1.62 to 2.70), which looks like a duplicated value.

Limits & uncertainty

  1. 1
    All 16 studies were observational, so the links with HbA1c, prediabetes and diabetes cannot show that glucose problems cause muscle loss; the abstract's wording that high HbA1c 'lead to' loss of muscle mass is stronger than the design supports.
  2. 2
    The HbA1c and prediabetes findings rest on very few studies (3 and 1), and the estimates for diabetes and complications are identical in the abstract, so at least one is probably misreported.
  3. 3
    Only English full-text articles were included, and the abstract gives no heterogeneity statistics or numbers of participants. The authors' call for glucose control to prevent sarcopenia goes beyond what observational data show. This reading is based on the abstract only.

What to take from it

People with diabetes may have a higher chance of low muscle mass and strength, so strength and function are worth watching alongside blood sugar. The studies do not show that tighter glucose control prevents sarcopenia. How to manage diabetes, diet and exercise should be decided with your own clinician.

Reading your own data

If you track glucose with a CGM or HbA1c results, you can note them alongside simple muscle markers such as grip strength, chair stands, walking speed or body-composition trends from the same device. Look for trends over months, because single readings and consumer body-composition estimates are noisy.

How to read this evidence

Pooling observational studies does not remove their confounding. Check overlapping cohorts and whether relative effects are being confused with absolute benefits.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Aim

We performed a meta-analysis of observational studies to evaluate the association between the presence of sarcopenia and HbA1c, prediabetes, diabetes and diabetic complications.

Method

The PubMed, Embase, Cochrane and Web of Science databases were searched from inception to May 2021. We included full-text English language articles that reported the prevalence of sarcopenia in patients with and without diabetes. Quality assessment was performed according to the Newcastle- Ottawa scale for observational studies.

Results

Sixteen studies were included in the meta-analysis. Three studies showed that high HbA1c levels lead to loss of muscle mass, and one study involving prediabetes showed that people with prediabetes had lower muscle mass, strength, and performance than non-diabetic population. Seven studies showed that people with diabetes had a higher risk of sarcopenia than those without diabetes (combined OR: 2.09, 95% CI:1.62-2.70). The remaining five studies suggested that diabetic complications increased the risk of sarcopenia (combined OR: 2.09,95% CI:1.62-2.70).

Conclusion

High HbA1c levels, prediabetes, diabetes and diabetes complications were associated with an increased risk of sarcopenia. Therapeutic strategies addressed to avoid the conversion of IGT to diabetes and to optimize glycemic control are warranted to prevent or arrest sarcopenia in the diabetic population.

Sources & attribution

The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies.

Qiao YS, Chai YH, Gong HJ, Zhuldyz Z, Stehouwer CDA, Zhou JB, Simó R.

Frontiers in endocrinology · 2021-12-23

DOI: 10.3389/fendo.2021.782391 ↗PubMed · 35002965 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Overview of reviews

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

In-depth explainersRead study →
·Trial meta-analysis

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

In-depth explainersRead study →
·Observational meta-analysis

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

In-depth explainersRead study →
·Trial meta-analysis

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

In-depth explainersRead study →
Strength & muscle →